Global Oncology Academy
The Global Oncology Academy (GOA) is an educational platform for physicians and other healthcare professionals involved in oncology. Its mission is to increase knowledge regarding the disease course of specific cancers and address key elements for successful management. The GOA series will also share the science around innovations in combination therapies, oncology strategies, and new developments.
For more information about GOA, visit www.globaloncologyacademy.org.
121-135 of 350
Growth Recovery After Tovorafenib in Pediatric Low-Grade Gliomas: New Data
Project Oncology®Growth Recovery After Tovorafenib in Pediatric Low-Grade Gliomas: New Data
Alexandria May, PharmD, BCPS
Daniel Landi, MD
Unmet Needs in Endometrial Cancer: Bridging Gaps in Treatment and Equity
Project Oncology®Unmet Needs in Endometrial Cancer: Bridging Gaps in Treatment and Equity
Brian Slomovitz, MD
Reducing Endometrial Cancer Risk: Targeting Modifiable Risk Factors
Project Oncology®Reducing Endometrial Cancer Risk: Targeting Modifiable Risk Factors
Brian Slomovitz, MD
Targeting Ribosome Maturation: A Preclinical Strategy for Triple-Negative Breast Cancer
Project Oncology®Targeting Ribosome Maturation: A Preclinical Strategy for Triple-Negative Breast Cancer
Ryan Quigley
Modern Era, New Outcomes: Survival Trends in Breast Cancer Brain Metastases
Project Oncology®Modern Era, New Outcomes: Survival Trends in Breast Cancer Brain Metastases
Ryan Quigley
Dexamethasone Timing and Infusion Reactions in HER2+ Breast Cancer
Project Oncology®Dexamethasone Timing and Infusion Reactions in HER2+ Breast Cancer
- advertisement
Early Adulthood Weight Gain Linked to Breast Tissue Complexity Changes
Project Oncology®Early Adulthood Weight Gain Linked to Breast Tissue Complexity Changes
The Future of Immunotherapy: Advancing Care in Endometrial Cancer
Project Oncology®The Future of Immunotherapy: Advancing Care in Endometrial Cancer
Casey Cosgrove, MD
CLL17 Trial Insights: Fixed-Duration vs Continuous Therapy in Frontline CLL
Project Oncology®CLL17 Trial Insights: Fixed-Duration vs Continuous Therapy in Frontline CLL
Ryan Quigley
Real-World Cases in Pediatric Low-Grade Glioma: Exploring Targeted Therapies
Project Oncology®Real-World Cases in Pediatric Low-Grade Glioma: Exploring Targeted Therapies
Alexandria May, PharmD, BCPS
Angela Waanders, MD, MPH, MS
Ashley S. Margol, MD, MS
Advances in Colorectal Cancer Detection: Exploring the Role of Blood-Based Tests
GI InsightsAdvances in Colorectal Cancer Detection: Exploring the Role of Blood-Based Tests
Peter Buch, MD, FACG, AGAF, FACP
Aasma Shaukat, MD, MPH
10-Year PORTEC-3 Outcomes: Chemoradiotherapy in High-Risk Endometrial Cancer
Project Oncology®10-Year PORTEC-3 Outcomes: Chemoradiotherapy in High-Risk Endometrial Cancer
- advertisement
Evaluating a Lower-Intensity Treatment Regimen in AML: Phase 2 Results from PARADIGM
Project Oncology®Evaluating a Lower-Intensity Treatment Regimen in AML: Phase 2 Results from PARADIGM
Ryan Quigley
Predicting Prognosis in DLBCL: The Role of Immune-Related Gene Signatures
Project Oncology®Predicting Prognosis in DLBCL: The Role of Immune-Related Gene Signatures
Refining Risk, Reducing Burden: ENDORISK-2 and Preoperative Stratification in Endometrial Cancer
Project Oncology®Refining Risk, Reducing Burden: ENDORISK-2 and Preoperative Stratification in Endometrial Cancer
